Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide monotherapy for focal epilepsy with comorbid ADHD in children
ChiCTR2300075071Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lacosamide in Focal Onset Epilepsy and attention deficit hyperactivity disorder (ADHD), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: SNAP-IV score and Epilepsy control situation. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
lacosamide
03
Conditions
Focal Onset Epilepsyattention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ChiCTR2300075071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075071.